Glycogen synthase kinase 3 (GSK-3) is an "old enzyme" discovered about 20 years ago. However, there is a renewed interested in this enzyme in the twenty-first century because of the very promising potential of its inhibitors for the treatment of several diseases as neurodegenerative disorders (Alzheimer's disease), type 2 diabetes, depression and bipolar disorders, stroke, acute inflammatory processes, cancer, and so forth. Consequently, GSK-3 is considered as one of the most promising drug targets. Along this line, recent years have witnessed the birth of several chemical families of GSK-3 inhibitors with varying selectivity. These compounds have been extensively tested, and shown great potential for treatment of diseases that have no current effective treatment. Gathered and systematically analyzed in this volume is the relevant up-to-date information concerning GSK-3 and its known inhibitors. This volume should be useful to researchers interested in drug design and development, especially those researchers directly involved in the fascinating world of GSK-3.
Ana Martinez, Ana Castro, and Miguel Medina
Was this article helpful?
Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...